On the other hand, the Kantarjian’s group demonstrated that single-agent blinatumomab (a bispecific antibody that binds to CD19 tumor cells and CD3 T cells) showed antileukemia activity in adult patients with relapsed or refractory B-precursor ALL, in which 2% patients had grade 3 CRS.60 In 2019, Li et al. found that CRS was also induced after the treatment of anti-HER2/CD3 T cell-dependent bispecific (TDB) antibody.61 It is worth noting that systemic serum expression of TNF-α, IL-2, and IL-6 was substantially increased only at 2 h after treatment. This evidence concerns the gene TNF and neoplasm.